Nasdaq Mdgl News Today

Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) is scheduled to post its quarterly earnings results before the market opens on Tuesday, May 7th. Analysts expect Madrigal Pharmaceuticals to post earnings of ($6.06) per share for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link. Madrigal Pharmaceuticals […]

Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) will be releasing its earnings data before the market opens on Tuesday, May 7th. Analysts expect Madrigal Pharmaceuticals to post earnings of ($6.06) per share for the quarter. Investors interested in listening to the company’s conference call can do so using this link. Madrigal Pharmaceuticals (NASDAQ:MDGL – Get […]

Analysts at Bank of America started coverage on shares of Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) in a research report issued to clients and investors on Monday, Marketbeat Ratings reports. The firm set an “underperform” rating and a $150.00 price target on the biopharmaceutical company’s stock. Bank of America‘s target price would suggest a […]

Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) fell 3.3% during mid-day trading on Wednesday . The company traded as low as $225.22 and last traded at $225.22. 43,731 shares were traded during trading, a decline of 92% from the average session volume of 525,723 shares. The stock had previously closed at $232.98. […]

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) has received an average rating of “Moderate Buy” from the ten research firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 12-month price […]

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) CMO Rebecca Taub sold 27,845 shares of the stock in a transaction on Wednesday, April 3rd. The shares were sold at an average price of $245.14, for a total value of $6,825,923.30. Following the transaction, the chief marketing officer now directly owns 458,999 shares of the company’s […]

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) Director Paul A. Friedman sold 18,710 shares of the stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $242.96, for a total value of $4,545,781.60. Following the completion of the sale, the director now directly owns 185,735 […]

Profund Advisors LLC raised its holdings in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 32.6% in the 3rd quarter, Holdings Channel.com reports. The firm owned 7,723 shares of the biopharmaceutical company’s stock after buying an additional 1,898 shares during the quarter. Profund Advisors LLC’s holdings in Madrigal Pharmaceuticals were worth $1,128,000 at […]

Connor Clark & Lunn Investment Management Ltd. lowered its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 21.4% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 51,686 shares of the biopharmaceutical company’s stock after selling 14,075 shares during the […]

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) has earned an average rating of “Moderate Buy” from the seven research firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 1-year price objective […]